 MIRAMAR, Fla., Feb. 24, 2021 GLOBE NEWSWIRE -- Generex Biotechnology Corporation OTCQB:GNBT today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen HLA allele, which is one of hundreds of alleles in the human immune system. HLAs are proteins - or markers -found on most cells in your body. Your immune system uses these markers to recognize which cells belong in your body and which do not. So, for example, HLA is used to match patients and donors for bone marrow or organ transplants. The Ii-Key is specific for human HLA, so therefore does not work in other species, making it difficult to evaluate vaccine efficacy in animal models. The DR4 transgenic mouse provides an opportunity to evaluate the ability of Ii-Key vaccines to generate immune responses in an animal model, recognizing that the DR4 allele is only one of dozens of human HLA epitopes contained in the Ii-Key-SARS-CoV-2 vaccine. 